11. Myasthenia gravis Clinical trials / Disease details
Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-000895-40-DK (EUCTR) | 28/03/2019 | 26/02/2019 | Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis | Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis - BETA-MG | Myasthenia Gravis MedDRA version: 21.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: Salbutamol WZF 4 mg INN or Proposed INN: Salbutamol Other descriptive name: SALBUTAMOL SULFATE PH. EUR. | Aarhus University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 3 | Denmark | ||
| 2 | ChiCTR1800017696 | 2016-07-01 | 2018-08-10 | Effect of Magnesium Sulfate on Muscle Strength in Patients with Myasthenia Gravis | Effect of Magnesium Sulfate on Muscle Strength in Patients with Myasthenia Gravis | Myasthenia Gravis | Group A:Magnesium Sulfate;Group B:Normal saline; | The University of Hong Kong-Shenzhen Hospital | NULL | Recruiting | 18 | 60 | Both | Group A:30;Group B:30; | China |